EUVIMEDEUVIMED entdecken
Multizentrische Studie

Antiseizure medication reduction in long‐term video‐electroencephalographic monitoring for presurgical evaluation: A multicenter safety and efficacy analysis

Renate van Griethuysen, Charlotte J J van Asch iD, Willem M Otte iD, Herm Lamberink, Josemir W Sander iD, Mireille D Bourez-Swart, Lotte de Jong, Albert J Colon, Kees P J Braun, NeedtoStop Study Group

Epilepsia · 2025

DOI: 10.1111/epi.18572 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Epilepsia, 2025. Verfasst von Renate van Griethuysen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Stichting Epilepsie Instellingen Nederland, Heemstede, the Netherlands. Hauptthemen laut MEDLINE: Anticonvulsants, Electroencephalography, Drug Resistant Epilepsy, Epilepsies, Partial. Die Arbeit nennt 18 Literaturangaben. Gefördert von: MING of de 'vrienden van UMC Utrecht', Christelijke Vereniging voor de verpleging van Lijders aan Epilepsie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

In people with refractory focal epilepsy, long‐term video‐electroencephalographic monitoring (LT‐VEEG) is a valuable tool for surgical evaluation. Antiseizure medication (ASM) is often tapered during LT‐VEEG. ASM reduction may increase the risk of complications such as status epilepticus, and efficacy has not been established. We characterized contributing factors to successful and safe LT‐VEEG within a large multicenter dataset.

Methods

Adults and children were included from eight tertiary epilepsy centers in Europe for whom LT‐VEEG was part of the preoperative assessment for epilepsy surgery from May 2017 until January 2022. We collected demographics, baseline seizure frequency, ASM use and reductions or complete discontinuation, outcome (successful LT‐VEEG), and complications during ASM withdrawal/LT‐VEEG. We performed multivariate regression analysis to determine factors contributing to risks of complications and successful LT‐VEEG.

Results

We included 843 people. LT‐VEEG was successful in 70%. ASM was tapered in 756 persons (90%). Five hundred forty‐four persons started reduction of ASM before LT‐VEEG, of whom 72% reduced it at home. Baseline seizure frequency had a strong influence on ASM withdrawal policy. In people with a lower baseline seizure frequency, ASM was more likely to be tapered, and the reduction was more often initiated before the start of the LT‐VEEG. The extent of ASM dose reduction was identified as a critical factor contributing to a successful LT‐VEEG. ASM reduction increased the chance of complications; 10% had a complication compared to 1% without reduction. Starting ASM reduction before LT‐VEEG did not increase the risk of complications. Significance ASM reduction contributes to a successful LT‐VEEG in people with a lower baseline seizure frequency and is relatively safe, taking specific factors into account. The risk of adverse events is higher when ASM is reduced, regardless of timing or setting (outpatient vs. in‐hospital).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsElectroencephalographyDrug Resistant EpilepsyEpilepsies, PartialPreoperative CareHumansMaleFemaleAdultMiddle AgedChildAdolescentYoung AdultVideo RecordingTreatment OutcomeChild, Preschool

Stichwörter der Autor:innen

adverse eventsepilepsymedication withdrawalpresurgicalriskseizuressuccess

Substanzen

Anticonvulsants

Autor:innen und Institutionen

  • Stichting Epilepsie Instellingen Nederland, Heemstede, the Netherlands.
  • Department of (Child) Neurology and Neurosurgery, member of European Reference Network EpiCARE, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
  • University College London Queen Square Institute of Neurology, London, UK.
  • Department of Neurology, West China Hospital, Sichuan University, Chengdu, China.
  • Kempenhaeghe Academic Center for Epileptology, Heeze, the Netherlands.
  • Centre d'Etudes et Therapiede L'epilepsie, CHU-Martinique, Fort-de-France, France.

ORCID-Profile: Charlotte J J van Asch, Willem M Otte, Josemir W Sander

Förderung

  • MING of de 'vrienden van UMC Utrecht'
  • Christelijke Vereniging voor de verpleging van Lijders aan Epilepsie

Zitieren

APA

van Griethuysen, R., van Asch, C. J. J., Otte, W. M., Lamberink, H., Sander, J. W., Bourez-Swart, M. D., de Jong, L., Colon, A. J., Braun, K. P. J., & NeedtoStop Study Group (2025). Antiseizure medication reduction in long‐term video‐electroencephalographic monitoring for presurgical evaluation: A multicenter safety and efficacy analysis. Epilepsia. https://doi.org/10.1111/epi.18572

Vancouver

van Griethuysen R, van Asch CJJ, Otte WM, Lamberink H, Sander JW, Bourez-Swart MD, et al. Antiseizure medication reduction in long‐term video‐electroencephalographic monitoring for presurgical evaluation: A multicenter safety and efficacy analysis. Epilepsia. 2025. doi:10.1111/epi.18572

BibTeX
@article{vanGriethuysen2025,
  author = {van Griethuysen, Renate and van Asch, Charlotte J J and Otte, Willem M and Lamberink, Herm and Sander, Josemir W and Bourez-Swart, Mireille D and de Jong, Lotte and Colon, Albert J and Braun, Kees P J and NeedtoStop Study Group, NeedtoStop Study Group},
  title = {Antiseizure medication reduction in long‐term video‐electroencephalographic monitoring for presurgical evaluation: A multicenter safety and efficacy analysis},
  journal = {Epilepsia},
  year = {2025},
  doi = {10.1111/epi.18572}
}
Kostenlos starten →